Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

POSPÍŠILOVÁ Šárka SUTTON Lesley-Ann MALČÍKOVÁ Jitka TAUSCH Eugen ROSSI Davide MONTSERRAT Emili MORENO Carol STAMATOPOULOS Kostas GAIDANO Gianluca ROSENQUIST Richard GHIA Paolo

Year of publication 2016
Type Article in Periodical
Magazine / Source Haematologica
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.haematologica.org/content/101/3/263.full.pdf+html
Doi http://dx.doi.org/10.3324/haematol.2015.139246
Field Oncology and hematology
Keywords CLONAL EVOLUTION; MUTATIONS; SURVIVAL; TRIAL; PROGRESSION; IMPACT; CLL
Description T he prognostication of patients with chronic lympho- cytic leukemia (CLL) currently relies on both clinical and biological parameters (Figure 1). The prime exam- ple concerns the TP53 gene, whereby inactivation of TP53 , resulting from either a mutation or chromosome 17p deletion, is associated with a short time to progression, an early need for treatment, and an overall dismal outcome. 1,2 The presence of TP53 aberrations is also a strong predictor of treatment response, as patients carrying such lesions respond poorly to standard chemoimmunotherapy (CIT) (i.e. fludarabine, cyclophosphamide, and rituximab). 3 Although TP53 abnor- malities are infrequent at diagnosis (5%-10%), they are found in 40%-50% of advanced or therapy-refractory cases, hence underscoring the need to re-assess TP53 gene status as the dis- ease progresses and clones evolve.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.